共 50 条
- [21] Maintenance olaparib plus bevacizumab (bev) after platinum-based chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): Efficacy by timing of surgery and residual tumor status in the Phase III PAOLA-1 trialGYNECOLOGIC ONCOLOGY, 2020, 159 : 19 - 19Grimm, C.Cropet, C.Ray-Coquard, I.
- [22] The cost-effectiveness analysis of maintenance olaparib plus Bevacizumab in patients with advanced ovarian cancer: based on the final survival results from PAOLA-1 trialJournal of Ovarian Research, 16Youwen ZhuKun LiuHui CaoHong Zhu
- [23] Efficacy and safety of maintenance olaparib and bevacizumab (bev) in ovarian cancer (OC) patients (pts) aged ≥65 years (y) from the PAOLA-1/ENGOT-ov25 first-line trialANNALS OF ONCOLOGY, 2021, 32 : S737 - S738Sabatier, R.Rousseau, F.Joly, F.Cropet, C.Montegut, C.Frindte, J.Cinieri, S.Guerra-Alia, E. M.Bogner, G.Yoshida, H.Vergote, I.Colombo, N.Hietanen, S.Largillier, R.Canzler, U.Gratet, A.Marme, F.Pujade-Lauraine, E.Favier, L.Ray-Coquard, I. L.
- [24] Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trialEUROPEAN JOURNAL OF CANCER, 2023, 181 : 42 - 52Sabatier, RenaudRousseau, FrederiqueJoly, FlorenceCropet, ClaireMontegut, ColineFrindte, JohannaCinieri, SaverioAlia, Eva M. GuerraPolterauer, StephanYoshida, HiroyukiVergote, IgnaceColombo, NicolettaHietanen, SakariLargillier, RemiCanzler, UlrichGratet, AlainMarme, FrederikFavier, LaurePujade-Lauraine, EricRay-Coquard, Isabelle
- [25] PARPi monotherapy as first-line maintenance following chemotherapy plus bevacizumab in advanced ovarian cancer.JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Kudrik, Fred J.Vasudevan, AnupamaEnglish, SandyGart, MikeOladipo, TaofikatHartman, JohnIadeluca, Laura L.
- [26] Homologous recombination repair mutation gene panels (excluding BRCA) are not predictive of maintenance olaparib plus bevacizumab efficacy in the first-line PAOLA-1/ENGOT-ov25 trialGYNECOLOGIC ONCOLOGY, 2021, 162 : S26 - S27Pujade-Lauraine, EricBrown, JessicaBarnicle, AlanRowe, PhilLao-Sirieix, PierreCriscione, Stevendu Bois, AndreasLorusso, DomenicaRomero, IgnacioPetru, EdgarYoshida, HiroyukiVergote, IgnaceColombo, NicolettaHietanen, SakariProvansal, MagaliSchmalfeldt, BarbaraPignata, SandroMartin-Lorente, CristinaBerton, DominiqueRunnebaum, IngoRay-Coquard, Isabelle
- [27] Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trialEUROPEAN JOURNAL OF CANCER, 2022, 174 : 221 - 231Gonzalez-Martin, AntonioDesauw, ChristopheHeitz, FlorianCropet, ClaireGargiulo, PieraBerger, ReginaOchi, HiroyukiVergote, IgnaceColombo, NicolettaMirza, Mansoor R.Tazi, YoussefCanzler, UlrichZamagni, ClaudioGuerra-Alia, Eva M.Levache, Charles B.Marme, FrederikBazan, Fernandode Gregorio, NikolausDohollou, NadineFasching, Peter A.Scambia, GiovanniRubio-Perez, Maria J.Milenkova, TsvetaCostan, CristinaPautier, PatriciaRay-Coquard, Isabelle
- [28] Maintenance olaparib plus bevacizumab (bev) after platinum-based chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): Efficacy by BRCA1 or BRCA2 mutation in the phase III PAOLA-1 trial.JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Lorusso, DomenicaLotz, Jean-PierreHarter, PhilippCropet, ClairePerez, Maria Jesus RubioSchauer, ChristianMatsumoto, TakashiVergote, IgnaceColombo, NicolettaNoettrup, Trine JakobiBourgeois, Hugues PierreSchnelzer, AndreasPignata, SandreGarcia, YolandaProvansal, MagaliHanker, Lars ChristianBerton, DominiqueBauerschlag, DirkJoly, FlorenceRay-Coquard, Isabelle Laure
- [29] Olaparib as maintenance treatment following first-line platinum-based chemotherapy in patients with a germline BRCA mutation and metastatic pancreatic cancer phase III POLO trialANNALS OF ONCOLOGY, 2019, 30Golan, T.Hammel, P.Reni, M.Van Cutsen, E.Macarulla, T.Hall, M.Park, J.Hochhauser, D.Arnold, D.Oh, D.Reinacher-Shick, A.Tortora, G.Alguel, H.O'Reilly, E.McGuinness, D.Cui, K.Schlienger, K.Locker, G.Kindler, H.
- [30] Phase II OVARIO study of niraparib plus bevacizumab therapy in advanced ovarian cancer following front-line platinum-based chemotherapy with bevacizumabGYNECOLOGIC ONCOLOGY, 2020, 159 : 3 - 4Hardesty, M. M.Krivak, T.Wright, G. S.Hamilton, E.Fleming, E. L.Gupta, D.Keeton, E.Chen, J.Clements, A.Gray, H. J.Konecny, G. E.Moore, R. G.Richardson, D. L.